Shibuki, Taro
Sasaki, Mitsuhito
Yamaguchi, Shota
Inoue, Kanae
Taira, Tomonao
Satake, Tomoyuki
Watanabe, Kazuo
Imaoka, Hiroshi
Mitsunaga, Shuichi
Fujisawa, Takeshi
Tomizawa, Kento
Oyoshi, Hidekazu
Nakamura, Masaki
Hojo, Hidehiro
Ikeda, Masafumi
Article History
Received: 20 June 2023
Accepted: 23 October 2023
First Online: 31 October 2023
Change Date: 12 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13014-023-02377-3
Declarations
:
: This study was conducted with the approval of the Institutional Review Board of National Cancer Center Hospital East, Japan (No. 2020-209), and in compliance with the principles laid down in the Declaration of Helsinki. Because this study was a retrospective observational study carried out in Japan, the need to obtain informed consent from the patients was waived by the Institutional Review Board of National Cancer Center Hospital East (No. 2020-209).
: Not applicable.
: MI has received research funding (institution) from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai, Chiome Bioscience, Delta-Fly Pharma, Eisai, Eli Lilly Japan, Invitae, MSD,J-Pharma, Merck biopharma, Merus N.V., Novartis, Nihon Servier, Ono, Pfizer, and Syneos Health, consulted for AstraZeneca, Chugai, MSD, Nihon Servier, and Novartis, and received speaker honoraria from AbbVie, AstraZeneca, Chugai, Eisai, Eli Lilly Japan, Fujifilm Toyama Chemical, Guardant Health Japan, Incyte Biosciences Japan, MSD, Nihon Servier, Novartis, Nippon Kayaku, Ono, Taisho Pharmaceutical, Teijin, Takeda, Taiho, and Yakult. SM has received research funding from Chugai, Astellas, Toray, Ajinomoto, and Pfizer, and received speaker honoraria from Ono, Toray, and Otsuka. HI has received research funding from Ono, and Novartis, consulted for Nihon Servier, and Kaneka Medix, and received speaker honoraria from Yakult, AstraZeneca, Nihon Servier, Kaneka Medix, Boston Scientific, and SB-Kawasumi Laboratories. MN has received personal fees from AstraZeneca, MSD, Varian Medical Systems, and Illumina outside of the scope of the submitted work. The other authors certify that they have no competing interests to declare.